By otakuyassine3@gmail.com 
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twenty brokerages that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $49.94.
Several analysts have recently weighed in on APLS shares. JPMorgan Chase & Co. dropped their price objective on shares of Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Oppenheimer cut their price objective on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Citigroup reduced their price objective on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. William Blair initiated coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They issued an “outperform” rating for the company. Finally, Scotiabank reduced their price target on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 6th.
Read Our Latest Report on APLS
Apellis Pharmaceuticals Stock Performance
Shares of NASDAQ:APLS opened at $32.68 on Friday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The business’s fifty day moving average price is $30.75 and its two-hundred day moving average price is $34.37. Apellis Pharmaceuticals has a fifty-two week low of $24.34 and a fifty-two week high of $73.80. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of -16.10 and a beta of 0.94.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same period in the previous year, the company posted ($1.17) EPS. The firm’s revenue for the quarter was up 78.3% compared to the same quarter last year. As a group, analysts predict that Apellis Pharmaceuticals will post -1.72 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its holdings in Apellis Pharmaceuticals by 6.9% in the second quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company’s stock valued at $13,242,000 after purchasing an additional 22,273 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Apellis Pharmaceuticals by 15.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,614 shares of the company’s stock valued at $752,000 after acquiring an additional 2,635 shares during the period. Panagora Asset Management Inc. bought a new position in Apellis Pharmaceuticals during the 2nd quarter worth approximately $907,000. Peregrine Capital Management LLC grew its holdings in Apellis Pharmaceuticals by 23.3% during the second quarter. Peregrine Capital Management LLC now owns 114,279 shares of the company’s stock valued at $4,384,000 after purchasing an additional 21,619 shares during the period. Finally, nVerses Capital LLC increased its stake in Apellis Pharmaceuticals by 300.0% in the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after purchasing an additional 2,100 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Featured Stories
Receive News & Ratings for Apellis Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.